Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2011 by China-Japan Friendship Hospital.
Recruitment status was:  Not yet recruiting
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Guochun Wang, China-Japan Friendship Hospital Identifier:
First received: November 15, 2011
Last updated: November 22, 2011
Last verified: November 2011
  1. To establish a BMD reference database of Beijing's urban population, China.
  2. To determine the prevalences and risk factors of osteoporosis and osteopenia in Beijing's urban population, China.
  3. To describe the 25OHD level and estimate the prevalence of vitamin D insufficiency and deficiency of Beijing's urban population, China.
  4. Estimation of the prevalence of osteoporotic fracture (vertebral) in over age of 60 of Beijing's urban population, China.


Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population

Resource links provided by NLM:

Further study details as provided by China-Japan Friendship Hospital:

Primary Outcome Measures:
  • A BMD reference database of Beijing's urban population, China. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The prevalences and risk factors of osteoporosis and osteopenia in Beijing's urban population, China. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
complete blood

Estimated Enrollment: 10000
Study Start Date: January 2012
Estimated Study Completion Date: March 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)

Detailed Description:

With one of the biggest populations in the world, China was heavily suffered from osteoporosis. The prevalence of osteoporosis in China even is increasing fast in recent years, which are especially notable in urban population. This change maybe due to the conditions including rapid economic growth, increase in life expectancy, and changes in lifestyle. Studies in 1998 including 13 separately small samples (no more than 1000 people) from 9 provinces in China showed that the prevalence of osteoporosis and osteopenia were 5.3-6.2% and 5.8-11.2%, respectively. These estimates were higher by approximately 1% than those reported in 1995. In 2002, according to DEXA results in connection with population census in 2000, Xiaoguang Cheng et al. took a survey in 600 people who were separately studied in previously 10 research projects and find that patients with osteoporosis account for approximately 6.97% of the total China population.

Although these studies have documented a remarkable increase in the prevalence of osteoporosis in China, these estimations were all based on small samples. No risk factors related with osteoporosis and osteopenia, esp. hypovitaminosis D on osteoporosis and osteopenia, have been analyzed yet. So it is impossible to make any forecast of osteoporosis or give any instruction for intervention.

Thus this study designed to provide current and reliable data on the prevalence of osteoporosis and osteopenia and associated risk factors correlation coefficients in the Beijing's urban adult population.


Ages Eligible for Study:   20 Years to 79 Years   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The study will comprise 10,000 people aging from 20 to 79 residing in urban Beijing, China. All of them are members of Beijing Municipal Health Insurance (Beijing is a city that buy medical insurances for all of its residents).

Inclusion Criteria:

  • 20 to 79 residents in urban Beijing, China.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01476150

China, Beijing
China-Japan Friendship Hospital
Beijing, Beijing, China, 100029
Sponsors and Collaborators
China-Japan Friendship Hospital
Merck Sharp & Dohme Corp.
Study Chair: Shukun Yao China-Japan Friendship Hospital
  More Information

Responsible Party: Guochun Wang, Chief, Dept. of Rheumatology & Immunology, China-Japan Friendship Hospital, China-Japan Friendship Hospital Identifier: NCT01476150     History of Changes
Other Study ID Numbers: CJFSRI-OP 
Study First Received: November 15, 2011
Last Updated: November 22, 2011
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases processed this record on January 18, 2017